Santhera Pharmaceuticals Holding AG (SWX: SANN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 100.72M |
| Revenue (ttm) | 113.59M |
| Net Income (ttm) | 62.86M |
| Shares Out | 12.11M |
| EPS (ttm) | 5.70 |
| PE Ratio | 1.46 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,105 |
| Open | 8.05 |
| Previous Close | 8.03 |
| Day's Range | 8.05 - 8.55 |
| 52-Week Range | 7.21 - 11.44 |
| Beta | 0.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 12, 2024 |
About SANN
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceutic... [Read more]
Financial Performance
Financial StatementsNews
Santhera Pharmaceuticals reports 1H results
Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe
Pratteln, Switzerland, September 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive distribution agreement with GENESIS Pharma for AGAMREE® (vamorolone) for the trea...